This month’s announcements on new technology, awards, partnerships, and more include eClinical Solutions, COTA, Greenphire, and other notable companies.
This month’s announcements on new technology, awards, partnerships, and more include eClinical Solutions, COTA, Greenphire, and other notable companies.
Contract research organization (CRO) Emmes has introduced its third-generation version of Advantage eClinical. The cloud platform (available as a standalone software product) is designed to accelerate study builds, increase flexibility, and provide insights to sponsors.einsights to clinical trial sponsors of all sizes.
“One of the challenges many smaller biotechs face in the market is they don’t have access to an integrated technology platform for their trials; options are incredibly limited and expensive, and they are often inflexible and lack support,” commented Hemang Maniar, Emmes chief information officer. “This is exactly what we have set out to address with our third-generation Advantage eClinical platform.”
Trial financial management solutions provider Greenphire has been named the 2022 Best MedTech Startup by market intelligence organization MedTech Breakthrough. Greenphire reportedly was chosen (for the third consecutive year) due to its focus on improving patent experience.
Jim Murphy, CEO of Greenphire. “For the past 13 years, we’ve consistently worked to improve the participant payment and travel process with our purpose-built solutions to ensure sites are satisfied and patients are empowered. I am thrilled this effort is being acknowledged by our clients and industry organizations.”
Real-world data and analytics company COTA has announced an expansion of its partnership with the Miami Cancer Institute, which aims to improve standard of care and access for minority cancer patient populations. The institute will use COTA’s analytics platform to improve understanding on how various factors contribute to disparities.
Leonard Kalman, MD, Miami Cancer Institute’s executive deputy director and chief medical officer, said, “Delayed cancer diagnosis for a patient frequently leads to poorer outcomes. Our hope is that this collaborative research will identify the patients who are most at-risk for delayed diagnosis so we can increase education and expand access to routine cancer screenings for these populations.”
eClinical Solutions has launched its elluminate statistical computing environment. Integrated with the elluminate Clinical Data Cloud, the SCE is designed to provide one centralized place for all data, metadata, programs, and results, increasing the efficiency, traceability, and visibility of statistical analyses.
“The adoption of digital and decentralized clinical t models has accelerated and our industry now faces increasing amounts of complex clinical data; to stay ahead, the demand for a foundational platform that automates end to end clinical data flow has grown significantly across all segments of the life sciences market,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “Our SCE will reduce the manual work involved with standardizing and analyzing large volumes of trial data and help bring treatments to patients faster.”
Aptar CSP Technologies has announced its Activ-Blister packaging solutions for oral slide dose drugs is now available in the EMEA region. The move (part of the company’s plans to expand Activ-Blister production globally (comes out of a collaboration between the company, Uhlmann, and Ivers-Lee.
“Expanding global manufacturing sites for Activ-Blister technology reflects our commitment to delivering global access to innovative active material science solutions for patients and consumers,” said Badre Hammond, vice president of commercial operations and GM APAC. “With manufacturing capabilities now available in in both the US and EMEA, we will turn our attention to bringing production of this technology to the Asia market.”
AI-centric drug discovery specialist BenevolentAI has announced that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its drug development portfolio. This is the third novel target from the collaboration that has been identified using the Benevolent Platform across two disease areas (IPF and chronic kidney disease) and subsequently validated and selected for portfolio entry by the pharmaceutical company.
Maria Belvis (senior vice president, and head of research and early development for respiratory and immunology with AstraZeneca) said, “IPF is a devastating disease with median survival of around three years and there is a serious need for better treatment options. At AstraZeneca, we are continuously striving to improve our R&D productivity in order to quickly bring potentially innovative treatments to complex diseases such as IPF. Our partnership with BenevolentAI furthers our commitment and we are proud to deliver a second novel target for IPF to our portfolio.”
Gb Sciences recently showcased its PhAROS drug discovery platform at the ALCOR Drug Discovery Platform Summit. The platform uses artificial intelligence (AI) and machine learning to identify and predict the efficacy of combinations of novel active ingredients from plants.
The company reports that to date, the platform has identified potential plant-inspired therapeutic mixtures for the treatment of neurological disorders, inflammation, anxiety, depression, heart disease, metabolic syndrome, chronic pain, and other conditions. These minimum essential mixtures were then validated in cell and now animal models in preparation for safety and efficacy testing in human clinical trials.
Mdgroup, a provider of clinical study technologies, has launched its Primarius3 enterprise solution Primarius3. The product is designed to help patients, sponsors, sites, healthcare practitioners, and other stakeholders connect in one centralized, integrated platform.
Caroline Jackson, Mdgroup executive vice president of patient services, said, “Patients are at the heart of everything that we do at Mdgroup. This latest technology, featuring our enhanced patient mobile app, will significantly streamline their experiences when submitting expense claims and travel requests.”
